Shantha Biotechnics

Shantha Biotechnics Limited is an Indian biotechnology company headquartered in Hyderabad, India. It is the first Indian company to develop, manufacture and market recombinant human healthcare products in India. The company is a wholly owned subsidiary of Sanofi group.[1]

Shantha Biotechnics Limited
Private Limited Company
IndustryBiotechnology
Founded1993
FounderK. I. Varaprasad Reddy
HeadquartersMedchal, Hyderabad, Telangana, India
Key people
K. I. Varaprasad Reddy (Chairman)
Harish Iyer (CEO)
ProductsRecombinant DNA Vaccines
ParentSanofi
WebsiteShanthabiotech.com

Shantha Biotechnics caters to major international markets including Asia-Pacific, Africa, Commonwealth of Independent States, and Latin America in addition to international organisations UNICEF and PAHO.

History
The manufacturing facility of Shantha Biotechnics near the Genome Valley

Shantha Biotechnics, Ltd. began with the initiatives of Dr. K. I. Varaprasad Reddy and Khalil Ahmed. Varaprasad and Ahmed established the company in 1993 to produce affordable drugs for the general population, while maintaining international standards in quality.[1] The project originated as an R&D project at Osmania University under the industry-university interactive programme in 1993, and later operated from the Center for Cellular and Molecular Biology until an independent research and development facility was built.

In 2006 the European biotech major Mérieux Alliance bought a 60% stake in Shantha Biotechnics at a valuation of $175 million.[2]

In 2009, the vaccine division of French pharmacological company Sanofi Pasteur acquired the stake held by Mérieux Alliance, valuing Shantha Biotech at Euro 550 million (over Rs 3,770 crore).[3]

Over time, Sanofi acquired a further stake in Shantha Biotechnics and in 2013 acquired 100% of the company.[4]

Products

Drugs developed by Shantha include SHANVAC-B, SHANFERON, SHANKINASE, SHANPOIETIN, pediatric combination vaccines Shantetra and Shan5, SHAN HIB-DPT, SHAN HIB and SHANTT.

Insuman cartridges project

The main object of the Insuman Cartridges Project is to produce insulin at a lower cost. It is in Medak district Telangana state. The project cost is 460 crore.[5]

gollark: All OS components are MIT-licensed.
gollark: No, PotatOS is committed to open source.
gollark: > THE SOFTWARE IS PROVIDED "AS IS", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE AUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER LIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM, OUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE SOFTWARE.
gollark: Oh right, the code is MIT-license too.
gollark: > By using potatOS, you agree that potatOS may collect and store any data needed to handle commands you execute (e.g. files stored on your computer), or to do anything else it has been programmed to do, or anything whatsoever. privacy policy line 6

See also

References
  1. "Shantha Biotech to launch 5-in-1 pediatric vaccine - CNBC-TV18". Moneycontrol.com. Retrieved 28 September 2012.
  2. "Sanofi-Aventis Takes Control Of Shantha Biotechnics". VCCircle. Retrieved 19 September 2015.
  3. Somashekar Mulugu. "Business Line : Companies News : Top level changes at Shantha Biotechnics". Thehindubusinessline.com. Retrieved 28 September 2012.
  4. "Sanofi infusing $122M to complete buy-out of Shantha Biotech and further expansion". VCCircle. Retrieved 19 September 2015.
  5. Details: Insuman Cartridges Project
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.